Deliver Your News to the World

Clinical and Cost Benefits Promote Utilisation of Cardiac Diagnostics in Primary Healthcare


June 06, 2006

London, United Kingdom — Across Europe, the market for cardiac markers used in primary care is experiencing a tremendous rate of growth due to their precise diagnostic properties. With rapid turn-around times (TAT), these cardiac markers will enable cost reduction and improved patient outcomes. Over the next three to four years, cardiac markers will be implemented more effectively in primary care to support decreased bed occupancy, hospital costs and physician time.

Frost & Sullivan ( finds that the European Primary Care Cardiac Diagnostics Market earned revenues of $50.3 million in 2005 and estimates this to reach $149.4 million in 2012.

“Cardiac point-of-care testing (POCT) offers many benefits for primary care, particularly in improving TAT results and in allowing the prescription of earlier and more appropriate treatment, “ notes Frost & Sullivan Team Leader of Clinical Diagnostics Dr. Fiona Rahman. “POCT can better satisfy customer needs with the introduction of new cardiac markers; in addition to boosting patient confidence with on-the-spot tests that improve disease diagnosis and monitoring, these diagnostics also enable the implementation of programmes designed to prevent the onset of diseases.“

In switching from conventional methods of heart disease diagnosis to these novel markers, cardiologists have developed the market. The use of cardiac diagnostic tests, such as troponins and NPs, in primary care is poised to grow due to the introduction of point of care (POC) technologies.

“These cardiac markers will give more valuable indications during emergencies towards determining appropriate treatments and the level of risk of a heart attack,” adds Dr. Rahman. “The rapid TAT of cardiac markers will reduce costs and improve the treatment of patients admitted with chest pain.”

However, although the science behind cardiac assessment is growing, the cardiology community still requires further education and training on the advantages of these novel risk markers. Medical communities in the United Kingdom and France are hesitant to adopt new methods of diagnosing, treating and managing patients without adequate corroboration that they will make significantly enhanced contributions to patient well being and cost savings.

“Physicians are sceptical about adopting novel markers and continue to rely on tried and tested methods of diagnosis, which are cheaper and do not require validation and scientific support,” explains Dr. Rahman. “These end users are reluctant to experiment with expensive markers, which are essential to complement more traditional diagnostic methods.”

Therefore, the challenge for manufacturers will be to promote cost-effective cardiac diagnostics markers as well as to encourage end users to trial and adopt risk tests as routine diagnosis.

Ultimately, increasing awareness about the benefits of using cardiac markers in primary care will benefit both healthcare providers and patients. Informed patients who understand the concept of cardiac markers are more likely to request the most current and novel markers available. This increased demand will result in primary care sites having more discussions regarding the merits of investing in the latest cardiac diagnostic technologies. In instances of innovative diagnostic tests, the need for end-user education is essential if the revenues are to be realised.

European Utilisation of Cardiac Markers in Primary Care is part of the Drug Discovery and Diagnostic Technologies Subscription, which also includes research in the following markets: European Acute Cardiac Diagnostics Markets, Cardiac Diagnostics Markets in Europe - Risk Markers and European Primary Care Diagnostics Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Utilisation of Cardiac Markers in Primary Care (B946- 55) then send an e-mail to Radhika Menon Thedore- Corporate Communications at with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit

European Utilisation of Cardiac Markers in Primary Care
B946- 55


Radhika Menon Theodore
Corporate Communications - Europe
P: +91 44 42044541
F: +91 44 24314264

Melina Trevino
Corporate Communications - Americas
P: 210.247.2440
F: 210.348.1003

Surbhi Dedhia
Corporate Communications - India
P: +91 22 5001 3431

Jasminder Kaur
Corporate Communications - Asia Pacific
P: +65 68900937

Sharmin Jassal
Corporate Communications - Australia
P: + 61 2 8247 8900
F: + 61 2 9252 8066

Keywords in this release: cardiac markers, primary care, turn-around times, TAT, physicians, hospitals, healthcare, Europe, primary care cardiac diagnostics, cardiac point-of-care testing, POCT, disease diagnosis, disease monitoring, conventional heart disease diagnosis methods, cardiologists, cardiac diagnostic tests, troponins, NPs, point of care technologies, POC technologies, cardiac assessment, heart attack, United Kingdom, France, cardiac diagnostic technologies


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.